PRE 14C 1 ea0212785-pre14c_health.htm PRELIMINARY INFORMATION STATEMENT

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Schedule 14C

 

Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

 

(Amendment No. )

 

Check the appropriate box:

 

☒Preliminary Information Statement

 

☐Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2))

 

☐Definitive Information Statement

 

HEALTHCARE TRIANGLE, INC.

(Name of Registrant As Specified In Its Charter)

 

Payment of Filing Fee (Check the appropriate box):

 

☒No fee required

 

☐Fee paid previously with preliminary materials.

 

☐Fee computed on table in exhibit required by Item 25(b) of Schedule 14A (17 CFR 240.14a-101) per Item 1 of this Schedule and Exchange Act Rules 14c-5(g) and 0-11

 

 

 

 

 

PRELIMINARY INFORMATION STATEMENT

 

NOTICE OF STOCKHOLDER ACTION BY WRITTEN CONSENT

 

HEALTHCARE TRIANGLE, INC.

 

7901 Stoneridge Drive, Suite 220

Pleasanton, California 94588

 

WE ARE NOT ASKING YOU FOR A PROXY, AND YOU ARE REQUESTED NOT TO SEND US A PROXY. NO PROXY CARD HAS BEEN ENCLOSED WITH THIS INFORMATION STATEMENT.

 

To the Stockholders of Healthcare Triangle, Inc.:

 

NOTICE IS HEREBY GIVEN THAT SecureKloud Technologies, Inc., a Nevada corporation (“SecureKloud”) and Suresh Venkatachari (together, the “Majority Stockholders”), who collectively own 83.8% of the voting power of Healthcare Triangle, Inc., a Delaware corporation (the “Company”), acting by written consent in lieu of a special meeting pursuant to Section 228 of the General Corporation Law of the State of Delaware (the “DGCL”), approved, to the extent required by Nasdaq Listing Rules 5635(a) and 5635(b), the issuance by the Company of 12,000,000 shares of the Company’s restricted common stock (“Common Stock”) to SecureKloud pursuant to the terms and conditions of an Asset Transfer Agreement dated August 27, 2024, between the Company and SecureKloud. Pursuant to the Asset Transfer Agreement, in exchange for the 12,000,000 shares of Common Stock to be issued to SecureKloud, the Company will acquire substantially all of the business, assets, and operations relating to cloud and technology domain that currently form part of SecureKloud. The Majority Stockholders executed their written consent approving the Asset Transfer Agreement and the issuance of the 12,000,000 shares of Common Stock to SecureKloud on September [*], 2024 (the “Written Consent”). Pursuant to Rule 14c-2 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the actions approved by the Written Consent may not be taken until 20 days after the date that we transmit this Information Statement to our stockholders.

 

No action is required by you. The accompanying Information Statement is furnished only to inform our stockholders who did not execute the Written Consent, in accordance with the requirements of the Securities and Exchange Commission’s rules and regulations and will serve as written notice to stockholders of the Company pursuant to Section 228 of DGCL.

 

This Information Statement is being transmitted on or about September [*], 2024 to our stockholders of record as of the close of business on September 3, 2024.

 

Pursuant to rules adopted by the Securities and Exchange Commission, you may access a copy of the information statement at www.siebertnet.com.

 

By Order of the Board of Directors

 

Dated: September __, 2024

 Sincerely,
   
  /s/ Thyagarajan Ramachandran
  Name: Thyagarajan Ramachandran
  Title: Chief Financial Officer

 

 

 

HEALTHCARE TRIANGLE, INC.

 

7901 Stoneridge Drive, Suite 220

Pleasanton, California 94588

 

INFORMATION STATEMENT

 

September ___, 2024

 

This Information Statement is furnished to inform our shareholders of actions taken by SecureKloud Technologies, Inc. and Suresh Venkatachari (together, the “Majority Stockholders”).

 

THE ACTIONS TAKEN HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION, NOR HAS THE SECURITIES AND EXCHANGE COMMISSION PASSED UPON THE FAIRNESS OR MERITS OF THE ACTIONS TAKEN, NOR UPON THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED IN THIS INFORMATION STATEMENT. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.

 

WE ARE NOT ASKING YOU FOR A PROXY, AND YOU ARE REQUESTED NOT TO SEND US A PROXY. NO PROXY CARD HAS BEEN ENCLOSED WITH THIS INFORMATION STATEMENT.

 

Healthcare Triangle, Inc. a Delaware corporation (“we”, “us”, “our” or the “Company”) has filed this Information Statement with the Securities and Exchange Commission (the “Commission”). Our board of directors (the “Board”) is transmitting this Information Statement to our shareholders of record as of the close of business on September 3, 2024 (the “Record Date”), pursuant to Rule 14c-2 promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). By furnishing this Information Statement to our shareholders, we are also providing notice of the action taken by written consent of the Majority Shareholder as required by Section 228 of the Delaware General Corporation Law (the “DGCL”).

 

The cost of preparing, printing and transmitting this Information Statement will be paid by us. We will reimburse brokerage firms and other custodians, nominees and fiduciaries for reasonable expenses incurred by them in transmitting this Information Statement to the beneficial owners of our common stock.

 

This Information Statement informs our shareholders that on September 3, 2024, the Majority Stockholders, acting by written consent in lieu of a special meeting, approved, to the extent required by Nasdaq Listing Rules 5635(a) and 5635(b), the issuance of 12,000,000 shares of our common stock pursuant to that certain Asset Transfer Agreement, dated as of August 27, 2024 between the Company and SecureKloud, Technologies, Inc., a Nevada corporation, the owner of 44.1% of our common stock and 24.7% of our voting power (the “Purchase Agreement”).

 

On September 3, 2024, Suresh Venkatachari owned 75,000 shares of our common stock representing 1.8% of the issues and outstanding shares of our common stock and 6,000 shares of our Series A Super Voting Preferred Stock, which vote with our common stock at a rate of 1,000 to 1 and together with his shares of common stock represent 59.2% of our voting power and SecureKloud owned 2,550,000 shares of our common stock, representing 44.1% of the issue and outstanding shares of our common stock and 24.7% of our voting power. SecureKloud is the Company’s largest owner of its common stock.

 

Accordingly, all necessary corporate approvals to comply with Nasdaq Listing Rules 5635(a) and 5635(b) have been obtained. We are not seeking approval from our remaining stockholders. This Information Statement is furnished solely for the purpose of informing our shareholders, in the manner required by the Exchange Act and Section 228 of the DGCL of the action taken by written consent of the Majority Stockholders. Pursuant to Rule 14c-2 under the Exchange Act, the action approved by written consent may not be taken until 20 days after the date that we transmit this Information Statement to our shareholders. This Information Statement is first being transmitted to our record date shareholders on or about September [*], 2024.

 

1

 

 

QUESTIONS AND ANSWERS ABOUT THIS INFORMATION STATEMENT

 

Q. Why am I being furnished with this Information Statement?

 

A. The Exchange Act and the DGCL require us to provide you with information regarding the actions taken by written consent of the Majority Stockholders in lieu of a meeting. Your vote is neither required nor requested.

 

Q. Was stockholder approval of the potential issuance of common stock pursuant to the Asset Transfer Agreement required?

 

A. Shareholder approval of the issuance of common stock is required under Nasdaq Listing Rules 5635(a) and 5635(b). Nasdaq Listing Rule 5635(a) in relevant part requires listed companies to obtain shareholder approval prior to the issuance of securities in connection with the acquisition of the stock or assets of another company if (x) the common stock has or will have upon issuance voting power equal to or in excess of 20% of the voting power outstanding before the issuance of stock or securities convertible into or exercisable for common stock or (y) any director, officer or substantial shareholder of the Company has a 5% or greater interest directly or indirectly, in the company or assets to be acquired or in the consideration to be paid in the transaction and the potential issuance of common stock could result in an increase in outstanding common shares or voting power of 5% or more. Nasdaq Listing Rule 5635(b) requires listed companies to obtain stockholder consent prior to the issuance of securities when the issuance or potential issuance will result in a change of control of the company. Nasdaq generally considers a change of control occurs when, as a result of the issuance, an investor or a group would own, or have the right to acquire, 20% or more of the outstanding shares of common stock or voting power and such ownership or voting power would be the largest ownership position.

 

Q. What do I need to do now?

 

A. Nothing. This Information Statement is furnished to you solely for your information and does not require or request you to do anything.

 

There are no rights of appraisal or similar rights of dissenters with respect to the Nasdaq Stockholder Approval.

 

PLEASE BE ADVISED THAT THIS IS ONLY AN INFORMATION STATEMENT. WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.

 

Our executive offices are located at 7901 Stoneridge Drive, Suite 220, Pleasanton, California 94588.

 

This Information Statement is first being sent or given to the holders of our outstanding shares of common stock and the holder of our Series A Super Voting Preferred Stock, our only classes of voting securities outstanding, on or about September ___, 2024. Each holder of record of shares of our shares of common stock and Series A Super Voting Preferred Stock at the close of business on September 3, 2024, is entitled to receive a copy of this Information Statement.

 

2

 

 

THE PROPOSED ACQUISITION AND STOCK ISSUANCE

 

Purpose of the Asset Transfer Agreement and the Transaction

 

The Board believes it is in the best interests of the Company to enter into the current transaction acquiring the assets from the buyer, in the amount of up to $7,200,000, which will be payable in shares of our Common Stock. The terms of the Asset Transfer Agreement are complex and only briefly summarized below. For further information, please see the full text of the Asset Transfer Agreement, which is attached as Annex A hereto. The discussion herein is qualified in its entirety by reference to the Asset Transfer Agreement. Please see the subsection entitled “—The Asset Transfer” below, for additional information and a summary of certain terms of the Asset Transfer Agreement. You are urged to carefully read the agreement in its entirety. The Board approved the Asset Transfer Agreement and the Transaction on August 27, 2024, and the Majority Stockholders approved the Asset Transfer Agreement and the Transaction by written consent delivered to the Company on September ___, 2024.

 

The Companies

 

Healthcare Triangle, Inc.

 

We are a healthcare information technology company focused on advancing innovative industry-transforming solutions in the sectors of cloud services, data science, and professional and managed services for the electronic health record (EHR), healthcare and life sciences industry.

 

Our approach leverages our proprietary technology platforms, extensive industry knowledge, and healthcare domain expertise to provide solutions and services that reinforce healthcare progress. Through our platform, solutions, and services, we support healthcare delivery organizations, healthcare insurance companies, pharmaceutical and Life Sciences, biotech companies, and medical device manufacturers in their efforts to improve data management, develop analytical insights into their operations, and deliver measurable clinical, financial, and operational improvements.

 

We offer a comprehensive suite of software, solutions, platforms and services that enables some of the world’s leading healthcare and pharma organizations to deliver personalized healthcare, precision medicine, advances in drug discovery, development and efficacy, collaborative research and development, respond to real world evidence, and accelerate their digital transformation. We combine our expertise in the healthcare technology domain, cloud technologies, DevOps and automation, data engineering, advanced analytics, AI/ML, Internet of things (“IoT”), security, compliance, and governance to deliver platforms and solutions that drive improved results in the complex workflows of Life Sciences, biotech, healthcare providers, and payers. Our differentiated solutions, enabled by intellectual property platforms provide advanced analytics, data science applications, and data aggregation in a secure, compliant and cost-effective manner to our customers. Our approach reinforces healthcare progress through advanced technology, extensive industry knowledge, and domain expertise.

 

Our deep expertise in healthcare allows us to reinforce our clients’ progress by accelerating their innovation. Our healthcare IT services include EHR and software implementation, optimization, extension to community partners, as well as application managed services, and backup and disaster recovery capabilities on public cloud. Our 24x7 managed services are used by hospitals and health systems, payers, Life Sciences, and biotech organizations in their effort to improve health outcomes and deliver deeper, more meaningful patient and consumer experiences. Through our services, our customers achieve return on investment in their technology by delivering measurable improvements. Combined with our software and solutions, our services provide clients with an end-to-end partnership for their technology innovation.

 

SecureKloud Technologies, Inc.

 

SecureKloud Technologies, Inc., a Nevada corporation (“SecureKloud”), and our largest shareholder of the Company, is a leading global information technology business transformation, secure cloud solutions and managed services provider headquartered in Plainsboro, NJ providing solutions – SMAC (Social, Mobile, Analytics and Cloud) for seamless connectivity between consumers, small, mid-size and large enterprises (the “Business”).

 

The principal executive offices of SecureKloud are located at 666 Plainsboro Road, Suite 448, Plainsboro, NJ 08536, USA.

 

3

 

 

Description of the Asset Transfer Agreement

 

This subsection of the information statement describes the material provisions of the Transaction and Asset Transfer Agreement, but does not purport to describe all of the terms of the Asset Transfer Agreement. The following summary is qualified in its entirety by reference to the complete text of the Asset Transfer Agreement, which is attached as Annex A hereto. You are urged to read the Asset Transfer Agreement in its entirety because it is the primary legal document that governs the proposed acquisition.

 

The Asset Transfer Agreement contains representations, warranties and covenants that the respective parties made to each other as of the date of the Asset Transfer Agreement or other specific dates. The assertions embodied in those representations, warranties and covenants were made for purposes of the contract among the respective parties and are subject to important qualifications and limitations agreed to by the parties in connection with negotiating the Asset Transfer Agreement. The representations, warranties and covenants in the Asset Transfer Agreement are also modified in important part by the underlying disclosure schedules, which are not filed publicly and which are subject to a contractual standard of materiality different from that generally applicable to stockholders and were used for the purpose of allocating risk among the parties rather than establishing matters as facts.

 

Consideration

 

The aggregate purchase price for our acquisition of SecureKloud’s assets as described in the Asset Transfer Agreement is $7,200,000, subject to adjustment as described below. The purchase price is completely comprised of newly issued 12,000,000 shares of our Common Stock, pegged at $0.60 per share.

 

Under this provision, SecureKloud shall deliver to the Company, without any encumbrances, “Transferred Assets” as used in the Asset Purchase Agreement, and which shall include all assets of the Business involved in cloud and technology domain, including, without limitation, each of the following:

 

●all assets (business contracts and employees);

 

●all immigration-related interests, obligations and liabilities of SecureKloud;

 

●all agreements, contracts, franchises, insurance policies, leases, property licenses, purchase orders, software licenses, software escrow agreements, technology licenses understandings, or arrangements relating to SecureKloud’s cloud and technology business, entered into by SecureKloud for or in connection with SecureKloud’s cloud and technology business;

 

●all government and regulatory permits, licenses, concessions, or other similar consents held by SecureKloud for or in connection with the SecureKloud’s cloud and technology business;
   
●the release from employment by SecureKloud of the employees connected with the SecureKloud’s cloud and technology business, who have been offered employment by the Company as on the closing date, and who have accepted such employment;

 

●all business and financial records and documents connected with or relating to SecureKloud’s cloud and technology business, including vouchers, invoices, books of accounts, tax records, tax returns, notices, filings, and all other documents and records (whether proprietary, confidential or otherwise) used for or in connected with SecureKloud’s cloud and technology business, owned, or controlled by SecureKloud or its agents, including any tax advisors, accountants, auditors or legal advisors.

 

Reasons for the Proposed Transaction

 

In evaluating the Asset Transfer Agreement and the proposed acquisition, our Board of Directors consulted with our management and its advisors and, in reaching its decision to approve the Asset Transfer Agreement and the Transactions contemplated by the Asset Transfer Agreement, our Board of Directors considered a variety of factors.

 

Our Board of Directors believed that, overall, the potential benefits of the proposed acquisition to our stockholders outweighed the risks and uncertainties of the proposed acquisition. In reaching its decision regarding the proposed acquisition, our Board did not quantify or otherwise assign relative weights to the specific factors. Moreover, each member of our Board applied his or her own personal business judgment and may have given different weights to different factors. Our Board did not undertake to make any specific determination as to whether any factor, or any particular aspect of any factor, supported or did not support its ultimate determination. Our Board based its recommendation on the totality of the information presented.

 

4

 

 

Consideration Offered to Stockholders

 

There is no consideration being offered to the Company’s stockholders.

 

Issuance Of Common Stock

 

Pursuant to the terms of the Asset Transfer Agreement, at the closing of the Transaction (the “Closing”), the Company will issue to SecureKloud approximately 12,000,000 shares of its restricted Common Stock as payment of the Purchase Price. The Purchase Agreement has been unanimously approved by the boards of directors of the Company and SecureKloud.

 

The Closing of the Transaction, currently scheduled for September 29, 2024, is subject to customary closing conditions including receiving required regulatory approvals and obtaining approval from the Company’s shareholders of the issuance of Common Stock in payment of the purchase price.

 

Reason for Stockholder Approval

 

Pursuant to Nasdaq Listing Rule 5635(a), if (x) the common stock has or will have upon issuance voting power equal to or in excess of 20% of the voting power outstanding before the issuance of stock or securities convertible into or exercisable for common stock or (y) an issuer intends to issue common stock or securities convertible into or exercisable for common stock, in connection with the acquisition of stock or assets of another company, which may equal or exceed 20% of the outstanding common stock or voting power on a pre-transaction basis, the issuer generally must obtain the prior approval of its stockholders. Pursuant to Nasdaq Stock Market Listing Rule 5635(b) requires listed companies to obtain stockholder consent prior to the issuance of securities when the issuance or potential issuance will result in a change of control of the company. Nasdaq generally considers a change of control occurs when, as a result of the issuance, an investor or a group would own, or have the right to acquire, 20% or more of the outstanding shares of common stock or voting power and such ownership or voting power would be the largest ownership position. The number of shares of common stock to be issued to the seller in the Asset Purchase Agreement upon would result in the issuance of a number of shares exceeding the threshold for which stockholder approval is required under Nasdaq Listing Rule 5635(a) and Nasdaq Listing Rule 5635(b). To ensure compliance with Nasdaq Listing Rule 5635(a) and Nasdaq Listing Rule(b), the Majority Stockholders approved the Asset Purchase Agreement and the Transaction.

 

No Interests of Related Persons

 

No director or executive officer of our company at any time since the beginning of the last fiscal year has any interest in the proposed acquisition.

 

No Appraisal Rights

 

Appraisal rights are not available to our stockholders in connection with the proposed acquisition.

 

Accounting Treatment

 

We will account for the proposed acquisition using the acquisition method of accounting in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 805 “Business Combinations” (“ASC 805”). In accordance with ASC 805, we will use our best estimates and assumptions to assign fair value to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. Goodwill of Appliances Connection will be measured as the excess of the purchase consideration over the fair value of the net tangible assets and identifiable assets acquired.

 

ACTIONS AUTHORIZED AND APPROVED

 

The actions that were taken by the Company’s Board of Directors and by its majority stockholder were the authorization and approval of the Asset Purchase Agreement and the Nasdaq Stockholder Approval, respectively.

 

5

 

 

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

 

The following table sets forth information with respect to the beneficial ownership of our common stock and our Series A Super Voting Preferred Stock, our only outstanding classes of capital stock having the right to vote on this matter, known by us as of the Record Date, by:

 

 

 ● each person or entity known by us to be the beneficial owner of more than 5% of our common stock;
     
  ● each of our directors;
     
  ● each of our executive officers; and
     
  ● all of our directors and executive officers as a group.

 

Beneficial ownership of the voting stock is determined in accordance with the rules of the United States Securities and Exchange Commission (the “SEC”) and includes any shares of Company voting stock over which a person exercises sole or shared voting or investment power, or of which a person has a right to acquire ownership at any time within 60 days of August 29, 2024. Except as otherwise indicated, we believe that the persons named in this table have sole voting and investment power with respect to all shares of voting stock held by them. Applicable percentage ownership in the following table is based on 5,666,781 shares of our common stock and 6,000 shares of our Series A Super Voting preferred stock issued and outstanding on August 29, 2024. As of August 29, 2024, there were 47 holders of our common stock and one holder of our Series A Super Voting preferred stock.

 

Except as otherwise indicated, the persons listed below have sole voting and investment power with respect to all shares of our common stock owned by them, except to the extent such power may be shared with a spouse. To our knowledge, none of the shares listed below are held under a voting trust or similar agreement, except as noted. To our knowledge, there is no arrangement, including any pledge by any person of securities of the Company, the operation of which may at a subsequent date result in a change in control of the Company.

 

   Number of Shares
Beneficially Owned		  Beneficial Ownership Percentages     
Name and Address of Beneficial Owner(1)  Title  Common
Stock		   Series A
Super Voting
Preferred
Stock(2)		   Percent of
Common
Stock		   Percent of
Series A Super Voting Preferred
Stock		   Percent of
Voting
Stock(3)		 
Officers and Directors                       
Thyagarajan Ramachandran  Chief Financial Officer   56,186(5)   —    1.0%   —    0.5%
                             
Shibu Kizhakevilayil  Director   32,732(6)   —    0.6%   —    0.3%
Ronald McClurg  Director   —    —    *    —     * 
Dave Rosa  Director   —    —    *    —    * 
Jainal Bhuiyan  Director   —    —    *    —    * 
Officers and Directors as a Group                          — 
       88,918         1.5%   N/A    0.8%
5% Stockholders                            
SecureKloud Technologies, Inc.(4)      2,550,000    —    44.1%   N/A     21.6%
Suresh Venkatachari      137,152(7)   6,000    2.4%   100    52.1%

 

*Less than 1%.

 

 (1)

 The principal address of the named officers, directors and 5% stockholders of the Company is c/o Healthcare Triangle, Inc, 7901, Stoneridge Dr, Suite # 220, Pleasanton, California 94588.

 

6

 

 

(2) Entitles the holder to 1,000 votes per share and votes with the common stock as a single class.

 

(3) Represents total ownership percentage with respect to all shares of common stock, options and Series A Super Voting Preferred Stock, as a single class.
   
(4) SecureKloud Technologies, Inc. is 60.71% owned by SecureKloud Technologies Limited which is a publicly traded company in India.
   
(5) Includes 41,186 shares of our common stock underlying stock options that have vested or are exercisable within 60 days of August 29, 2024.
   
(6) Includes 12,732 shares of our common stock underlying stock options that have vested or are exercisable within 60 days of August 29, 2024.
   
(7) Includes 62,152 shares of our common stock underlying stock options that have vested or are exercisable within 60 days of August 29, 2024.

 

INTERESTS OF CERTAIN PERSONS IN OR OPPOSITION TO

 

MATTERS TO BE ACTED UPON

 

None of the persons who have served as our officers or directors since the beginning of our last fiscal year, or any associates of such persons, have any substantial interest, direct or indirect, in the authorization and approval of the Asset Purchase Agreement or in the Nasdaq Stockholder Approval, other than the interests held by such persons through their respective beneficial ownership of the shares of our capital stock set forth above in the section entitled “Security Ownership of Certain Beneficial Owners and Management.” None of our directors opposed the authorization and approval of the Asset Purchase Agreement.

 

VOTE OBTAINED — DELAWARE LAW

 

Section 228 of the DGCL generally provides that any action required to be taken at a meeting of stockholders may be taken without a meeting, without prior notice and without a vote, if a written consent thereto is signed by stockholders having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. Pursuant to the Nasdaq Listing Rules, a majority of the outstanding voting shares of stock entitled to vote thereon is required in order to effectuate the Nasdaq Stockholder Approval. In order to eliminate the costs and management time involved in obtaining proxies and to effect the above action as early as possible in order to accomplish the purposes of the Company as herein described, the Board consented to the utilization of, and successfully obtained, written consent of the Majority Stockholder.

 

As of August 29, 2024, there were 5,666,781 shares of common stock of the Company and 6,000 shares of the Series A Super Voting Preferred Stock issued and outstanding. Each holder of common stock is entitled to one vote for each share held by such holder and the holder of the Series A Super Voting Preferred Stock has 1,000 votes per share and votes with the common stock as a single class. On August 29, 2024, stockholders holding in the aggregate 2,625,000 shares of common stock and 6,000 shares of the Series A Super Voting Preferred Stock or approximately 46.3% of the capital stock outstanding on such date having the right to vote on the Nasdaq Stockholder Approval, approved the Nasdaq Stockholder Approval.

 

DELIVERY OF DOCUMENTS TO SECURITY HOLDERS SHARING AN ADDRESS

 

Only one Information Statement is being delivered to multiple security holders sharing an address unless the Company has received contrary instructions from one or more of its security holders. The Company undertakes to deliver promptly and without charge, upon written or oral request, a separate copy of the information statement to a security holder at a shared address to which a single copy of the documents was delivered. Security holders sharing an address and receiving a single copy may send a request to receive separate information statements to the Company at the following address: Healthcare Triangle, Inc., 7901 Stoneridge Drive, Suite 220, Pleasanton, California 94588. Telephone: (925) 270-4812.

 

7

 

 

WHERE YOU CAN FIND MORE INFORMATION

 

We are subject to the information requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and file annual, quarterly, and special reports, proxy statements, and other information with the SEC. Our SEC filings are available to you on the SEC’s website at www.sec.gov. Documents we have filed with the SEC are also available on our website through the investors link at www.applieduvinc.com. Information contained on our website does not constitute a part of this prospectus and is not incorporated by reference herein.

 

You may request a copy of these filings, at no cost, by writing Healthcare Triangle, Inc. at 7901 Stoneridge Drive, Suite 220, Pleasanton, California 94588 or telephoning the Company at (925) 270-4812. Any statement contained in a document that is incorporated by reference will be modified or superseded for all purposes to the extent that a statement contained in this Information Statement (or in any other document that is subsequently filed with the SEC and incorporated by reference) modifies or is contrary to such previous statement. Any statement so modified or superseded will not be deemed a part of this Information Statement except as so modified or superseded.

 

Our common stock is traded on the Nasdaq Capital Market under the symbol “HCTI.”

 

Our transfer agent is VStock Transfer, LLC. Their address is 18 Lafayette Place, Woodmere, New York 11598 and their telephone number is (212) 828-8436.

 

INCORPORATION BY REFERENCE

 

Statements contained in this information statement, or in any document incorporated in this information statement by reference regarding the contents of other documents, are not necessarily complete and each such statement is qualified in its entirety by reference to that contract or other document filed as an exhibit with the SEC. The SEC allows us to “incorporate by reference” into this information statement certain documents we file with the SEC. This means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is considered to be part of this Information Statement, and later information that we file with the SEC, prior to the effective date of the actions set forth herein, will automatically update and supersede that information. We incorporate by reference all of the documents we filed since January 1, 2023 with the SEC and any documents filed by us pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Information Statement and prior to the effective date of the actions set forth herein. These include periodic reports, such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, as well as information or proxy statements (except for information furnished to the SEC that is not deemed to be “filed” for purposes of the Securities Exchange Act of 1934). Notwithstanding the foregoing, information furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference into this information statement.

 

Any person, including any beneficial owner, to whom this Information Statement is delivered may request copies of reports, proxy statements or other information concerning us, without charge, as described above in “Where You Can Find More Information.”

 

You should rely only on information contained in or incorporated by reference in this information statement. No persons have been authorized to give any information or to make any representations other than those contained in this information statement and, if given or made, such information or representations must not be relied upon as having been authorized by us or any other person.

 

THIS INFORMATION STATEMENT IS DATED SEPTEMBER ___, 2024. YOU SHOULD NOT ASSUME THAT THE INFORMATION CONTAINED IN THIS INFORMATION STATEMENT IS ACCURATE AS OF ANY DATE OTHER THAN THAT DATE, AND THE MAILING OF THIS INFORMATION STATEMENT TO STOCKHOLDERS DOES NOT CREATE ANY IMPLICATION TO THE CONTRARY.

 

8

 

 

This Information Statement is first being mailed or furnished to stockholders on or about September ___, 2024. The Company will pay all costs associated with the distribution of this Information Statement, including the costs of printing and mailing. The Company will reimburse brokerage firms and other custodians, nominees and fiduciaries for reasonable expenses incurred by them in sending this Information Statement to the beneficial owners of the Common Stock.

 

This Information Statement is provided to the stockholders only for information purposes in connection with the Certificate of Amendment, pursuant to and in accordance with Rule 14c-2 of the Exchange Act. Please carefully read this Information Statement.

 

By Order of the Board of Directors:

 

Dated: September ___, 2024

 Healthcare Triangle, Inc.
   
  /s/ Thyagarajan Ramachandran
  Name: Thyagarajan Ramachandran
  Title: Chief Financial Officer

 

9

 

 

 

 

 

 

ANNEX A

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ASSET TRANSFER AGREEMENT

 

AUGUST 27, 2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ASSET TRANSFER AGREEMENT

 

This ASSET TRANSFER AGREEMENT (the “Agreement”) is entered into as of August 27, 2024 (“Execution Date”) by and between:

 

(1)SecureKloud Technologies, Inc., a Nevada corporation, having its registered office at 666 Plainsboro Road, Suite 448, Plainsboro, NJ 08536, USA (the “Seller” which expression shall unless repugnant to the context or meaning thereof, mean and include its successors and administrators); and

 

(2)Healthcare Triangle, Inc., a Delaware corporation, having its principal office at 7901, Stoneridge Drive, Suite 220, Pleasanton, CA 94588 (hereinafter referred to as the “Purchaser” which expression shall unless repugnant to the context or meaning thereof, mean and include its successors and administrators).

 

(The Seller and the Purchaser are individually referred to in this Agreement as a “Party” and together as the “Parties”).

 

RECITALS:

 

WHEREAS: the Seller is a leading global information technology business transformation, secure cloud solutions and managed services provider headquartered in Plainsboro, NJ providing solutions – SMAC (Social, Mobile, Analytics and Cloud) for seamless connectivity between consumers, small, mid-size and large enterprises, (the “Business”);

 

WHEREAS: The Seller wishes to sell, transfer, convey and assign to the Purchaser, and the Purchaser wishes to purchase from the Seller the business, assets, and operations relating to cloud and technology domain that currently form part of the Seller’s Business (the “Transferred Assets”), as a whole and as a going concern in exchange for the issuance by the Purchaser to the Seller of 12,000,000 shares of the Purchaser’s Common Stock, on and subject to the terms and subject to the conditions specified in this Agreement (the “Purchaser Equity”).

 

WHEREAS: The Purchaser and Seller have passed appropriate board resolutions authorizing the execution, delivery and performance of this Agreement and the transactions contemplated hereby and authorizing their respective representatives to execute all documentation and undertake all actions in relation thereto; and

 

WHEREAS: The Seller and the Purchaser wish to record in this Agreement the terms of the proposed transfer of the Transferred Assets in consideration for the issuance of the Purchaser Equity by the Purchaser to the Seller.

 

AGREEMENT:

 

NOW THEREFORE, THE PARTIES AGREE AS FOLLOWS:

 

1. AGREEMENT TO SELL AND PURCHASE

 

1.1 Subject to the other provisions of this Agreement, the Seller hereby sells, conveys, transfers and assigns the Transferred Assets to the Purchaser, as a whole, and as a going concern, in consideration for the issuance to the Seller of the Purchaser Equity, in the manner and on the terms specified in this Agreement.

 

A-1

 

 

1.2 Subject to the other provisions of this Agreement, and based on the representations of the Seller contained in this Agreement (“Representations”), the Purchaser hereby purchases from the Seller the Transferred Assets in consideration for the issuance to the Seller of the Purchaser Equity of 12,000,000 shares at $0.60 per share1 valuing the transferred assets at USD 7.20 million, in the manner and on the terms specified in this Agreement.

 

1.3 The consideration of USD 7.20 million is payable in equity, subject to applicable withholding, in the form of applicable number of shares of Buyer’s capital stock calculated based on the average of the VWAPs for the 20 Trading Days immediately prior to the Closing Date (the “Closing Equity Consideration”).

 

1.4 Without prejudice to the generality of the foregoing, and subject to Clause 1.4 below, the term “Transferred Assets” as used in this Agreement shall include all assets of the Business involved in cloud and technology domain, including, without limitation, each of the following:

 

(i) All assets (business contracts and employees) owned by the Seller identified in Schedule 1.3(i): Transferred Tangible Assets to this Agreement (collectively, the “Transferred Tangible Assets”), free and clear of any liens, pledges, charges, mortgages, defects in title, objections, security interests, claims, options, rights of first offer or refusal, hypothecations, restrictions on transfer, or other encumbrances of any kind (“Encumbrances”);

 

(ii) all immigration-related interests, obligations and liabilities of the Seller as the original petitioning employer, including but not limited to those obligations, liabilities, and undertakings arising from and under attestations contained in the Labor Condition Applications (LCAs) filed with the U.S. Department of Labor for H-1B petitions filed by the Seller;

 

(iii) All agreements, contracts, franchises, insurance policies, leases, property licenses, purchase orders, software licenses, software escrow agreements, technology licenses understandings, or arrangements relating to the Seller’s cloud and technology business (“Arrangements”) entered into by the Seller for or in connection with the Seller’s cloud and technology business (“Transferred Contracts”) and listed and identified in Schedule 1.3(iii): Transferred Contracts to this Agreement;

 

(iv) Subject to obtaining approvals of any third parties as may be required, all Arrangements entered into by the Seller for or in connection with the Seller’s cloud and technology cloud and technology business (“Future Transferred Contracts”) and listed and identified in Schedule 1.3(iv):: Future Transferred Contracts to this Agreement, which Future Transferred Contracts shall be deemed assigned automatically and immediately upon receipt of the appropriate approvals of any third parties, as required;

 

(v) All government and regulatory permits, licenses, concessions, or other similar consents held by the Seller for or in connection with the Seller’s cloud and technology business (“Permits”), if and to the extent such Permits are valid and subsisting on the Closing Date and are capable of being transferred or assigned in accordance with applicable law, as listed and identified in Schedule 1.3(v): Permits to this Agreement;

 

 

1Based upon, and over and above the last reported closing price of Healthcare Triangle, Inc.’s Common Stock on Nasdaq, which was $0.58 per share.

 

A-2

 

 

(vi) The release from employment by the Seller of the employees connected with the Seller’s cloud and technology business, who have been offered employment by the Purchaser as on the Closing Date, who have accepted such employment, and who are identified in Schedule 1.3(vi): Transferred Employees to this Agreement (“Transferred Employees”);

 

(vii) All business and financial records and documents connected with or relating to the Seller’s cloud and technology business, including vouchers, invoices, books of accounts, tax records, tax returns, notices, filings, and all other documents and records (whether proprietary, confidential or otherwise) used for or in connected with the Seller’s cloud and technology business (“Business Records”), owned, or controlled by the Seller or its agents, including any tax advisors, accountants, auditors or legal advisors.

 

1.5 Notwithstanding anything contained in any other provision of this Agreement, the Seller’s cloud and technology business specifically and expressly excludes any and all libilities and obligations associated with the Seller’s Business and outstanding on the date hereof, other than those listed on Schedule 1.4: Transferred Liabilities.

 

2. CONSIDERATION

 

In consideration for the sale, transfer, assignment and conveyance of the Transferred Assets by the Seller, in accordance with the provisions hereof, the Purchaser shall issue to the Seller the Purchaser Equity pursuant to a Common Stock Purchase Agreement, in substantially the form attached as Exhibit A hereto.

 

3. TAX MATTERS AND OTHER COSTS

 

3.1 The Purchaser shall issue the Purchaser Equity to the Seller, in accordance with Clause 2 of this Agreement, for a transfer of the Transferred Assets, as a whole and on a going concern basis only, and accordingly the Parties agree that no goods and services tax, sales tax or customs duty or similar tax, or surcharge thereon shall be payable by the Purchaser to the Seller in connection with the sale of the Transferred Assets. If any goods and services tax, sales tax or customs duty or similar tax, or surcharge thereon is payable on the sale of the Transferred Assets, then such tax (other than any tax on the Seller’s income or the Seller’s capital gains) shall be borne by the Seller.

 

3.2 Where any tax is required to be withheld or deducted at source on any payment by any Party pursuant to this Agreement, the payor shall be entitled to withhold or deduct the same at source, as required by law, provided that the payor shall issue the recipient thereof with necessary certificates of such withholding or deduction at source in accordance with applicable law, and within the time periods stipulated.

 

3.3 The Seller shall bear all income and capital gains taxes payable by the Seller on account of the sale of the Transferred Assets pursuant to this Agreement.

 

3.4 The Purchaser shall bear the applicable taxes levied by any authorities whatsoever payable in connection with any deed or document required to be executed in relation to the conveyance or assignment, as the case may be, of any property included in the Transferred Assets.

 

3.5 Each Party shall bear the costs and charges of its own professional and legal advisors.

 

A-3

 

 

4. CLOSING

 

4.1 Closing shall take place at the Seller’s place of business on September 29, 2024, at 5:00 pm PST.

 

4.2 At Closing, the Seller shall execute and deliver the Assignment Deed, in substantially the form attached as Exhibit B hereto.

 

4.3 At Closing, the Parties shall complete each of the actions and steps required to complete the sale of the Transferred from the Seller to the Purchaser and the issuance of Purchaser Equity to Seller.

 

5. REPRESENTATIONS AND WARRANTIES

 

5.1 Each Party represents and warrants to the other as follows.

 

(i) It has all requisite power and authority to enter into and perform all its obligations under this Agreement.

 

(ii) It has taken all actions, obtained all regulatory, corporate and contractual authorizations, and submitted all notices or filings required to be submitted, for it to validly enter into this Agreement and perform all its obligations under this Agreement.

 

(iii) The execution and delivery of, or the performance of obligations under, this Agreement do not violate or conflict with any statute, rule, regulation, directive, other law, judgment, order, decree or award applicable to it or to any provision of its constituent documents, or any agreement, contract, promise, covenant, undertaking, representation or warranty, applicable to or made by it.

 

(iv) This Agreement constitutes legal, valid and binding obligations, enforceable against it in accordance with its terms.

 

5.2 The Seller hereby represents to the Purchaser, that to the best of its knowledge, each of the Representations set out in Schedule 5.2: Representations to this Agreement is true, materially accurate, and not misleading, as on the date of this Agreement and as on the Closing Date. Provided that such Representations are made subject to the following:

 

(i) The Representations are qualified to the extent such qualifications have been expressly set out in the disclosure schedule set out in Disclosure Schedule to this Agreement (“Disclosure Schedule”), in substantially the form attached as Exhibit C hereto;

 

A-4

 

 

(ii) Where any Representation is stated to be made to the Seller’s best knowledge, or where any Representation is similarly qualified, such Representation has been

 

(iii) made and shall be deemed to have been made after the exercise of reasonable diligence by the Seller;

 

(iv) Any Representation made expressly as of a specific date is true and correct as of that specific date only;

 

(v) Any Representation that addresses any specific circumstances or facts does not allow recourse to a general statement;

 

(vi) Each Representation is separate and independent and, save as expressly provided to the contrary, shall not be limited by inference from any other Representation or any other term of this Agreement.

 

5.3 The Seller shall not do, allow or procure to be done, any act or omission that would constitute a breach of any Representation, or that would make any Representation false, incomplete, inaccurate or misleading if they were so given.

 

5.4 The Seller covenants to disclose promptly to the Purchaser in writing, immediately upon becoming aware of the same, any matter, event, or circumstance (including any omission to act) that may arise or become known between the date of this Agreement and the Closing Date and that would render any Representation to be inaccurate or incomplete or that relate to the occurrence of any material adverse event.

 

6. CONFIDENTIALITY

 

6.1 For purposes of this Agreement, Confidential Information means all scientific, technical, trade, financial or business information or materials that are either proprietary or not publicly known that any Party (Discloser) may from time to time disclose or otherwise make available to the other Party (Recipient) in connection with or pursuant to this Agreement. Without prejudice to the generality of the foregoing, Confidential Information includes the provisions of this Agreement, and information and materials related to any activities of the Discloser whether or not such information is marked or identified as confidential or proprietary. Provided that in relation to any and all Confidential Information connected in any manner with the Transferred Assets, the Seller shall be deemed the Discloser of such Confidential Information prior to the Closing Date, and the Purchaser shall be deemed the Discloser of such Confidential Information after the Closing Date (notwithstanding the earlier disclosure of such information by the Seller to the Purchaser).

 

6.2 Notwithstanding anything contained in Clause 6.1, Confidential Information shall not include information that:

 

(i) at the time of disclosure, is known publicly or thereafter becomes known publicly through no fault attributable to the Recipient;

 

A-5

 

 

(ii) becomes available to the Recipient from a third party that is not legally prohibited from disclosing such information, provided such information was not acquired from the Discloser;

 

(iii) was developed by the Recipient independently of information obtained from the Discloser, as shown by the Recipient’s written records that predate the receipt of such information from the Discloser;

 

(iv) was already known to the Recipient before receipt from the Discloser, as shown by the Recipient’s written records that predate the receipt of such information from the Discloser; or

 

(v) is released with the prior written consent of the Discloser.

 

6.3 A disclosure of Confidential Information made by or on behalf of the Discloser, including by its employees, agents, consultants, affiliates or associates, as well as disclosure by any means (whether written or oral) or through any medium, and any disclosure made prior or subsequent to the date of this Agreement shall be deemed to be a disclosure of Confidential Information for purposes of this Agreement.

 

6.4 Each Discloser hereby represents, warrants and covenants that it is entitled to and will be entitled to disclose all Confidential Information disclosed pursuant to or in connection with this Agreement.

 

6.5 The Recipient hereby covenants to do each of the following for a period of two (2) years following the earlier of (a) the Closing Date or (b) the expiry or termination of this Agreement for any reason:

 

(i) Keep all Confidential Information in strict confidence, with at least the same level of care as it applies to keeping its own personal, financial or proprietary information confidential, and in any event no less than reasonable care to prevent the unauthorized disclosure or use of any Confidential Information;

 

(ii) Not use, modify, create any derivative works from, or otherwise deal in any Confidential Information, except when the Recipient is required to do so solely in connection with this Agreement, and then only as specified by the Discloser;

 

(iii) Not disclose any Confidential Information to any other persons or entities except persons who need access to the Confidential Information in connection with this Agreement, and who are bound by equivalent obligations of confidentiality; and

 

(iv) Notify the Discloser in writing immediately upon discovery of any unauthorized use or disclosure of any Confidential Information and reasonably cooperate with the Discloser to prevent any unauthorized disclosure or use of the Confidential Information and to mitigate any losses arising from such unauthorized disclosure or use.

 

Provided that if the Recipient is required to disclose any Confidential Information by reason of a legal requirement or by the order of a judicial or administrative authority or by the listing requirements of a recognized stock exchange on which the securities of the Recipient are publicly traded, the Recipient, to the extent reasonably practicable, shall send to the Discloser prior notice of such requirement in order to allow the Discloser reasonable opportunity to oppose such process or to obtain protective or confidential treatment of the Confidential Information, and to the extent that a protective order or other legal protection is not obtained by the Discloser, the Recipient shall disclose only that portion of the information that is legally required to be disclosed.

 

A-6

 

 

6.6 Subject to the other provisions of this Clause 6, the Recipient shall be liable for any breach of its covenants in Clause 6.5 by any person to whom any Confidential Information is disclosed or provided by the Recipient, and the Recipient undertakes to take any and all necessary actions, at its own cost and expense, to prevent or remedy such breach.

 

6.7 Upon expiration or termination of this Agreement or earlier upon receipt of a written request from the Discloser, the Recipient shall cease all use of the Confidential Information and promptly return to the Discloser all documents and materials of the Discloser that relate to or contain any Confidential Information without retaining copies thereof, except for one (1) copy that may be made and retained by the Recipient solely for record-keeping and purposes of assuring continued compliance with its obligations under this Agreement.

 

6.8 Unless otherwise expressly provided in this Agreement, the disclosure of Confidential Information shall not of itself grant the Recipient any right, title or interest in the Confidential Information, except the limited right to use the Confidential Information solely for the purposes specified pursuant to and in accordance with this Agreement.

 

6.9 The Recipient acknowledges and agrees that the Discloser is not making and shall not be deemed to have made any implied representations or warranties regarding the accuracy or completeness of any Confidential Information, but nothing contained in this Clause 6 shall affect any Representation or any other express representation or warranty made with regard to the accuracy or completeness of any Confidential Information.

 

6.10 The Parties agree that in addition to any other rights or remedies available under this Agreement, in the event of any breach or any threatened breach of any obligations under this Clause 6 where such breach or threatened breach is in any way attributable to the Recipient, monetary damages do not provide a sufficient remedy, and the Discloser shall be entitled to an injunction restraining and to seek specific performance by the Recipient of any obligation under this Clause 6.

 

7. INDEMNIFICATION

 

7.1 Subject to the other provisions of this Clause 7, from and after the Closing, the Seller shall indemnify the Purchaser and save and hold the Purchaser harmless against any and all judgments, awards, liabilities, losses, costs or damages, including reasonable fees and expenses of attorneys, accountants and other professional advisors, actually incurred, whether involving a dispute solely among the Parties or otherwise, and any costs, including reasonable fees and expenses of attorneys, accountants and other professional advisors, incurred in investigating, defending or settling any claim, action or cause of action (“Losses”) suffered, incurred or paid, directly or indirectly, by any of them as a result of, arising out of or related to any third party claims made against the Purchaser as a result of:

 

(i) any failure of any Representation of the Seller, in each case as qualified and modified by the relevant Disclosure Letter, to be true and correct in all material respects, in accordance with the provisions hereof; and/or

 

(ii) any breach of any covenant by the Seller in this Agreement.

 

7.2 The Representations contained in this Agreement, including the Disclosure Schedule and any document delivered pursuant to this Agreement, shall survive Closing until the date that is twenty-four (24) months after the Closing Date.

 

A-7

 

 

8. TERMINATION

 

This Agreement may not be terminated except by mutual consent of the Parties recorded in writing and then only on such terms as shall be recorded.

 

9. MISCELLANEOUS

 

9.1 The section and clause headings and captions used in this Agreement are for convenience and identification only; otherwise, they form no part of this Agreement and do not affect its interpretation or construction.

 

9.2 References to sections, clauses or schedules without further specification are references to sections and clauses of this Agreement.

 

9.3 References to this Agreement include all sections, clauses and schedules in this Agreement and all recitals to this Agreement, as amended from time to time in writing by the Parties in accordance with the provisions of this Agreement.

 

9.4 Any reference to a statute or any provision of a statute includes a reference to that statute or provision and any rule, regulation, notification, circular, or direction made or issued pursuant to that statute or provision, as may be from time to time modified or re-enacted, whether prior to or after the date of this Agreement.

 

9.5 References to the singular include references to the plural and vice versa.

 

9.6 Words denoting one grammatical gender include references to all grammatical genders.

 

9.7 When the term “include”, “including” or “including in particular” is used in this Agreement, such use means “include without limitation”, “including without limitation” and “including in particular and without limitation” respectively.

 

9.8 The laws of the State in California shall govern all matters arising out of or relating to this Agreement, including, its validity, interpretation, construction, performance, expiry, termination and enforcement.

 

9.9 Any controversy, claim, or dispute arising out of or in connection with this Agreement, including any question regarding its existence, validity or termination, shall be settled by arbitration administered by the American Arbitration Association in accordance with its arbitration rules, and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. A notice of, or request for, arbitration will not operate to stay, postpone or rescind the effectiveness of any demand for performance.

 

A-8

 

 

9.10 Subject to the provisions of Clause 9.9, the Parties hereby confirm that the courts in Alameda County, California have jurisdiction over the Parties in connection with this Agreement.

 

9.11 Any notice, communication, document or other instrument required to be given under this Agreement shall be in writing and given by sending it by recognized courier with acknowledgement of receipt requested, or by electronic mail to the addresses specified below, or such other addresses as have been previously notified by each Party to the other in accordance with the provisions of this Clause 9.11.

 

IF TO THE PURCHASER:

 

Healthcare Triangle, Inc.

 

Address: 7901 Stoneridge Dr, Suite 220

 Pleasanton, CA 94588

Attn: Thyagarajan Ramachandran

Tel.: 708-289-5111

Email: rt@healthcaretriangle.com

 

IF TO THE SELLER:

 

SecureKloud Technologies, Inc.

 

Address: 666 Plainsboro Road, Suite 448, Plainsboro, 

NJ 08536, USA

Attn: PK Chandrasekher

Tel.: 609-933-7196

Email: pk@securekloud.com

 

Any notice, direction or other instrument required or permitted to be given under this Agreement shall be deemed to have been validly and effectively given (i) if sent by recognized courier with acknowledgement of receipt requested, then on the date of such delivery or receipt if such date is a working day in the city where the recipient’s address is located or otherwise on the next working day, or (ii) if transmitted by electronic mail, then on the working day (in the city where the recipient’s address is located) following the date of transmission.

 

9.12 This Agreement contains all the promises, agreements, conditions and understandings between the Parties with respect to the subject matter of this Agreement, and supersedes all prior or contemporaneous promises, agreements, conditions and understandings, whether oral or written, with respect to such subject matter.

 

9.13 Each Party agrees to execute and deliver all further instruments and documents and to perform all other acts that may be reasonably necessary or expedient to further the purposes of this Agreement. Each Party will not, directly or indirectly, permit or condone any action or engage in any omission or inaction that might cause any undertaking or covenant, or any representation or warranty not to be satisfied or fulfilled, including any action or inaction that might cause any undertaking, covenant, representation or warranty not to be true, correct and accurate during the term of or the term required under this Agreement.

 

A-9

 

 

9.14 This Agreement may be executed in one or more counterparts, all of which together shall constitute one and the same instrument. Any Party may enter into this Agreement by executing a counterpart, and a delivery by email to the other Party of a scanned copy of any such executed counterpart shall be deemed to constitute delivery of the original counterpart.

 

9.15 No amendment of, supplement to or suspension of this Agreement shall be effective unless it is in writing and duly executed by both Parties.

 

9.16 No Party, without the prior written consent of the other Party, may assign to any other person any of its rights, or delegate or sub-contract to any other person, the performance of any of its obligations arising under or related to this Agreement.

 

9.17 This Agreement binds and benefits the successors and permitted assigns of each Party. Without prejudice to the foregoing, this Agreement does not confer any enforceable rights or remedies upon any person other than the Parties.

 

9.18 Nothing in this Agreement shall or shall be deemed to constitute a partnership between the Parties or to constitute any Party as the agent of the other Party for any purpose.

 

9.19 A Party shall not make or publish any announcement or press release concerning or connected with this Agreement, without the prior written consent of the other Party, unless otherwise required by law.

 

9.20 No provision of this Agreement shall be construed against a Party on the ground that it or its agents or advisors drafted such provision.

 

9.21 If any provision of this Agreement should be or become entirely or partly invalid or unenforceable, such invalidity or unenforceability shall not affect the validity or enforceability of any other provision of this Agreement. Any invalid or unenforceable provision shall be regarded as replaced by such valid and enforceable provision that as closely as possible reflects the economic purpose that the Parties hereto had pursued with the invalid or unenforceable provision.

 

[The remainder of this page has been deliberately left blank. The signature page and schedules follow]

 

A-10

 

 

IN WITNESS WHEREOF, the Parties have executed and delivered this Agreement effective as of the day and year first written above.

 

  SELLER:
     
  SecureKloud Technologies, INC.
     
  By:  
  Name: PK Chandrasekher
  Title: VP, Finance
     
  Address: 666 Plainsboro Road,
  Suite 448, Plainsboro,
    NJ 08536, USA
  Email: pk@securekloud.com
     
  PURCHASER:
     
  HEALTHCARE TRIANGLE, INC.
     
  By:  
  Name: Thyagarajan Ramachandran
  Title: Chief Financial Officer
   
  Address: 7901 Stoneridge Dr,
    Suite 220, Pleasanton, CA 94588
  Email: rt@healthcaretriangle.com

 

 

A-11